SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-22-013988
Filing Date
2022-04-08
Accepted
2022-04-08 16:07:42
Documents
71
Period of Report
2022-02-28

Document Format Files

Seq Description Document Type Size
1 10-Q nrix-10q_20220228.htm   iXBRL 10-Q 2661095
2 EX-10.1 nrix-ex101_270.htm EX-10.1 325334
3 EX-31.1 nrix-ex311_6.htm EX-31.1 21838
4 EX-31.2 nrix-ex312_10.htm EX-31.2 21776
5 EX-32.1 nrix-ex321_9.htm EX-32.1 12871
  Complete submission text file 0001564590-22-013988.txt   9494573

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA nrix-20220228.xsd EX-101.SCH 51250
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE nrix-20220228_cal.xml EX-101.CAL 47125
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nrix-20220228_def.xml EX-101.DEF 174753
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE nrix-20220228_lab.xml EX-101.LAB 412739
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nrix-20220228_pre.xml EX-101.PRE 317160
65 EXTRACTED XBRL INSTANCE DOCUMENT nrix-10q_20220228_htm.xml XML 1740759
Mailing Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158
Business Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158 (415) 660-5320
Nurix Therapeutics, Inc. (Filer) CIK: 0001549595 (see all company filings)

IRS No.: 270838048 | State of Incorp.: DE | Fiscal Year End: 1130
Type: 10-Q | Act: 34 | File No.: 001-39398 | Film No.: 22817055
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences